Medical researchers reported that blood-based biomarker assays used in the Alzheimer’s trial successfully detected therapeutic response within twelve weeks of treatment initiation, potentially simplifying future clinical monitoring protocols.
Diagnostic developers emphasized that accessible blood tests could replace invasive lumbar punctures and costly PET scans in routine neurodegenerative disease monitoring.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.news2026.example.com/alzheimers-research-11